| 000 | 01866 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515185827.0 | ||
| 264 | 0 | _c20100108 | |
| 008 | 201001s 0 0 eng d | ||
| 022 | _a1557-8593 | ||
| 024 | 7 |
_a10.1089/dia.2009.0041 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aComulada, Angel L | |
| 245 | 0 | 0 |
_aEfficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. _h[electronic resource] |
| 260 |
_bDiabetes technology & therapeutics _cSep 2009 |
||
| 300 |
_aS17-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Inhalation |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
| 650 | 0 | 4 | _aBody Mass Index |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aForced Expiratory Volume _xdrug effects |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin _xadministration & dosage |
| 650 | 0 | 4 |
_aInsulin Antibodies _xblood |
| 650 | 0 | 4 | _aInsulin Glargine |
| 650 | 0 | 4 | _aInsulin Lispro |
| 650 | 0 | 4 | _aInsulin, Long-Acting |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVital Capacity _xdrug effects |
| 700 | 1 | _aRenard, Eric | |
| 700 | 1 | _aNakano, Masako | |
| 700 | 1 | _aRais, Nadeem | |
| 700 | 1 | _aMao, Xuejing | |
| 700 | 1 | _aWebb, David M | |
| 700 | 1 | _aMilicevic, Zvonko | |
| 773 | 0 |
_tDiabetes technology & therapeutics _gvol. 11 Suppl 2 _gp. S17-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/dia.2009.0041 _zAvailable from publisher's website |
| 999 |
_c19169505 _d19169505 |
||